tradingkey.logo
tradingkey.logo
Buscar

Exact Sciences Corp

EXAS
Añadir a la lista de seguimiento
104.910USD
0.0000.00%
Cierre 06/29, 16:00ETCotizaciones retrasadas 15 min
20.03BCap. mercado
PérdidaP/E TTM

Más Datos de Exact Sciences Corp Compañía

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Información de Exact Sciences Corp

Símbolo de cotizaciónEXAS
Nombre de la empresaExact Sciences Corp
Fecha de salida a bolsaJan 30, 2001
Director ejecutivoConroy (Kevin T)
Número de empleados6900
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 30
Dirección5505 Endeavor Lane
CiudadMADISON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal53719
Teléfono16082845700
Sitio Webhttps://www.exactsciences.com/
Símbolo de cotizaciónEXAS
Fecha de salida a bolsaJan 30, 2001
Director ejecutivoConroy (Kevin T)

Ejecutivos de Exact Sciences Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Exact Sciences Corp?

Los cinco principales accionistas de Exact Sciences Corp son: Mr. Kevin T. Conroy

¿Cuántas instituciones poseen acciones de Exact Sciences Corp (EXAS)?

A fecha de 2026Q1, 1452 instituciones poseen acciones de Exact Sciences Corp, con un valor de mercado combinado de aproximadamente 147.12M, lo que representa el 77.07% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -48700001.00.

¿Cuál es la mayor fuente de ganancias de Exact Sciences Corp?

El 2026Q1, el segmento empresarial Commercial generó la ganancia más alta para Exact Sciences Corp, ascendiendo a 1.52B y representando el 46.79% de la ganancia total.
KeyAI